A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT06362759

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
Tourmaline Bio, Inc., a Novartis Company (from the registry)
Registry
  • NCT NCT06362759
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06362759. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-15 (actual); primary completion 2025-03-06 (actual). Results posted on 2026-08-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
Acronym
TRANQUILITY
Condition
Chronic Kidney Diseases
Condition
Chronic Kidney Insufficiency
Condition
Chronic Renal Diseases
Condition
Chronic Renal Insufficiency
Condition
Kidney Insufficiency, Chronic
Condition
C-Reactive Protein
Condition
High Sensitivity C-Reactive Protein
Condition
Hs-CRP
Condition
hsCRP
Intervention (Drug)
TOUR006 - 50 MG
Intervention (Drug)
TOUR006 - 25 MG
Intervention (Drug)
TOUR006 - 15 MG
Intervention (Other)
Placebo
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company (class: industry)

Record details

Record id
cardio:ct-nct06362759
Content hash
a66cc1cfe1f2b1e85b23ade5bf0c449348f0e4da30727c74aa45a0b35d5c6c3c